Candel’s Prostate Cancer Therapy Shows 30% DFS Improvement in Phase 3 Trial
Event summary
- Candel Therapeutics published Phase 3 trial results in The Lancet Oncology showing a 30% improvement in disease-free survival (DFS) for localized prostate cancer patients treated with aglatimagene besadenovec (CAN-2409) plus radiotherapy compared to placebo.
- The trial enrolled 745 patients and met its primary endpoint, with a hazard ratio of 0.70 (p=0.016) for DFS.
- Aglatimagene demonstrated an 80% pathological complete response rate in biopsies two years post-treatment, compared to 63% in the placebo group (p=0.0018).
- The company plans to submit a Biologics License Application (BLA) for aglatimagene in Q4 2026.
The big picture
Candel’s Phase 3 results for aglatimagene represent a significant milestone in the treatment of localized prostate cancer, an area with limited innovation over the past two decades. The data support the potential for aglatimagene to become a standard-of-care adjunct to radiotherapy, addressing a critical unmet need. The upcoming BLA submission will be a key inflection point for the company’s valuation and market positioning.
What we're watching
- Regulatory Pathway
- Whether the BLA submission in Q4 2026 will proceed smoothly, given the positive Phase 3 data and FDA’s prior designations.
- Commercialization Strategy
- How Candel plans to position aglatimagene in the competitive landscape of localized prostate cancer treatments.
- Pipeline Expansion
- The pace at which Candel advances its other multimodal immunotherapy candidates, particularly linoserpaturev (CAN-3110) in recurrent high-grade glioma.